ProCE Banner Activity

TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL

Conference Coverage

In this update from the phase I/II TRANSCEND CLL 004 trial, lisocabtagene maraleucel induced rapid, deep, and durable responses in patients with relapsed/refractory CLL/SLL, including those with progression after BTK inhibitor therapy and venetoclax failure.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.